{
  "generatedAt": "2026-09-28T15:55:00.543Z",
  "note": "HerpesVaccinations.com open data, licensed CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) — reuse freely with attribution to HerpesVaccinations.com. Editorial status is our sourced reading of the evidence; registry facts come from ClinicalTrials.gov with their own date. Not medical advice. See https://herpesvaccinations.com/methodology/",
  "research": [
    {
      "slug": "bnt163-phase1-idweek-2025",
      "url": "https://herpesvaccinations.com/research/bnt163-phase1-idweek-2025/",
      "title": "Safety and Immunogenicity of BNT163, a Trivalent mRNA HSV Vaccine Candidate for Genital Herpes",
      "venue": "Open Forum Infectious Diseases (IDWeek 2025)",
      "year": 2025,
      "doi": null,
      "pmid": null,
      "pmcid": "PMC12793109",
      "sourceUrl": "https://europepmc.org/article/PMC/PMC12793109",
      "pubStatus": "conference-abstract",
      "studyType": "phase 1",
      "textBasis": "abstract-only",
      "retracted": false,
      "relatedCandidates": [
        "bnt163",
        "upenn-trivalent-mrna"
      ],
      "summary": "A conference abstract (IDWeek 2025) reporting early safety and immune-response data from the first-in-human Phase 1 trial of BioNTech's trivalent mRNA candidate BNT163. As a Phase 1 report it addresses safety and immunogenicity, not whether the vaccine prevents genital herpes, and as a conference abstract it has not undergone full peer-reviewed publication.",
      "lastUpdated": "2026-06-30"
    },
    {
      "slug": "glycoprotein-g-hsv-2-vaccine-antigen-mice-2026",
      "url": "https://herpesvaccinations.com/research/glycoprotein-g-hsv-2-vaccine-antigen-mice-2026/",
      "title": "Glycoprotein G enables HSV-2 neuroinvasion and provides protection as a glycosylated vaccine antigen",
      "venue": "PLoS pathogens",
      "year": 2026,
      "doi": "10.1371/journal.ppat.1014339",
      "pmid": "42424315",
      "pmcid": "PMC13349171",
      "sourceUrl": "https://doi.org/10.1371/journal.ppat.1014339",
      "pubStatus": "peer-reviewed",
      "studyType": "animal",
      "textBasis": "full-text",
      "retracted": false,
      "relatedCandidates": [],
      "summary": "A mouse study examined membrane-associated glycoprotein G of HSV-2 (mgG-2) both as a factor in infection and as a recombinant vaccine antigen. Mice immunized three times with the glycosylated antigen and then challenged genitally survived more often, had lower disease scores and had less viral DNA in nerve tissue than mice immunized with the same antigen stripped of both its N- and O-linked sugars. The work is preclinical — this study reports no vaccination data in people — and the authors state that animal vaccine models have so far not predicted clinical outcomes.",
      "lastUpdated": "2026-09-27"
    },
    {
      "slug": "mrna-1608-phase1-2-interim-idweek-2025",
      "url": "https://herpesvaccinations.com/research/mrna-1608-phase1-2-interim-idweek-2025/",
      "title": "mRNA-1608, an mRNA-Based Therapeutic Genital Herpes Vaccine Candidate: Interim Safety, Immunogenicity and Clinical Endpoint Results from a Phase 1/2 Trial",
      "venue": "Open Forum Infectious Diseases (IDWeek 2025)",
      "year": 2025,
      "doi": null,
      "pmid": null,
      "pmcid": "PMC12792503",
      "sourceUrl": "https://europepmc.org/article/PMC/PMC12792503",
      "pubStatus": "conference-abstract",
      "studyType": "phase 1/2",
      "textBasis": "abstract-only",
      "retracted": false,
      "relatedCandidates": [
        "mrna-1608"
      ],
      "summary": "A conference abstract (IDWeek 2025) reporting interim safety, immunogenicity, and clinical-endpoint results from the Phase 1/2 dose-ranging trial of Moderna's therapeutic candidate mRNA-1608. The results are interim and from a conference abstract; Moderna discontinued the program in November 2025 as part of a portfolio prioritization, not a reported safety failure.",
      "lastUpdated": "2026-06-30"
    },
    {
      "slug": "trivalent-mrna-hsv1-eye-mouse-2026",
      "url": "https://herpesvaccinations.com/research/trivalent-mrna-hsv1-eye-mouse-2026/",
      "title": "Immunogenicity and Efficacy of a Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Against HSV-1 Eye Infection and Neuroinvasion in Mice",
      "venue": "Vaccines",
      "year": 2026,
      "doi": "10.3390/vaccines14030253",
      "pmid": "41893790",
      "pmcid": "PMC13030542",
      "sourceUrl": "https://doi.org/10.3390/vaccines14030253",
      "pubStatus": "peer-reviewed",
      "studyType": "animal",
      "textBasis": "full-text",
      "retracted": false,
      "relatedCandidates": [
        "upenn-trivalent-mrna",
        "bnt163"
      ],
      "summary": "A preclinical, peer-reviewed mouse study from the University of Pennsylvania group (Friedman, Cohen, Awasthi and colleagues) testing their trivalent gC2/gD2/gE2 nucleoside-modified mRNA-LNP vaccine — the same design behind BNT163 — against HSV-1 eye infection and spread to the nervous system. Findings are in an animal model and do not, on their own, establish protection in humans.",
      "lastUpdated": "2026-06-30"
    }
  ]
}